Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Mechanistically Focused Clinical Trials in Environmental Allergy and Immunotherapy

    Mechanistically Focused Clinical Trials in Environmental Allergy and Immunotherapy supports scientists conducting clinical trials to understand allergen immunotherapy and achieve lasting immune tolerance.

    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: Immune Tolerance Network

    Due Dates: Rolling (review upon receipt; open until samples are allocated)

    Funding Amounts: Total available funding and number of funded projects vary by year across ITN

    Summary: Supports novel clinical trials investigating mechanisms of environmental allergen immunotherapy and the induction of durable immune tolerance.

    Key Information: Open to scientists from academia, industry, and government; non-human and preclinical studies are not accepted.


    Description

    The Immune Tolerance Network (ITN), an international clinical research consortium supported by the National Institute of Allergy and Infectious Diseases, seeks short proposals for clinical trials evaluating the mechanisms of environmental allergen immunotherapy. ITN integrates hypothesis-driven mechanistic research into clinical trials to understand tolerance induction and maintenance, looking beyond traditional safety and efficacy endpoints.

    The call prioritizes allergen immunotherapy combined with immunomodulators, multi-allergen immunotherapy, and intralymphatic immunotherapy. Its goal is to advance approaches capable of producing sustained unresponsiveness and, ideally, long-term tolerance off therapy. ITN also welcomes compelling aeroallergen-related clinical trial proposals outside these three priorities. Ideal proposals have supporting preclinical data, some safety and efficacy experience, and a testable mechanism of tolerance induction.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.